Oncology Medical News about hyperbilirubinemia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
Cancer Chemotherapy and Pharmacology, 08/20/09

Meza–Junco J et al. – The isolated increase in serum bilirubin levels in patient was probably due to sorafenib–induced UGT1A1 inhibition that manifested itself due both to the patient having one UGT1A1*28 allele and the presence of underlying liver disease. Bilirubin elevations in patients treated with sorafenib could indicate progression or drug toxicity; hence, these possibilities need to be ruled out.

<< Previous
Erlotinib as salvage treatment after failure to first-line...

Next >>
Nuclear morphometry and texture analysis of B-cell non-Hodgkin...